Related Experiment Video
Updated: Apr 16, 2026
Metabolic Profile Analysis of Zebrafish Embryos
Published on: January 14, 2013
The cellular and molecular progression of mitochondrial dysfunction induced by 2,4-dinitrophenol in developing
Jennifer E Bestman1, Krista D Stackley1, Jennifer J Rahn1
1Medical University of South Carolina, Drug Discovery & Biomedical Sciences, 280 Calhoun Street, MSC 140, QE 219A, Charleston, SC 29425, USA.
Abstract:
The etiology of mitochondrial disease is poorly understood. Furthermore, treatment options are limited, and diagnostic methods often lack the sensitivity to detect disease in its early stages. Disrupted oxidative phosphorylation (OXPHOS) that inhibits ATP production is a common phenotype of mitochondrial disorders that can be induced in zebrafish by exposure to 2,4-dinitrophenol (DNP), a FDA-banned weight-loss agent and EPA-regulated environmental toxicant, traditionally used in research labs as an uncoupler of OXPHOS. Despite the DNP-induced OXPHOS inhibition we observed using in vivo respirometry, the development of the DNP-treated and control zebrafish were largely similar during the first half of embryogenesis. During this period, DNP-treated embryos induced gene expression of mitochondrial and nuclear genes that stimulated the production of new mitochondria and increased glycolysis to yield normal levels of ATP. DNP-treated embryos were incapable of sustaining this mitochondrial biogenic response past mid-embryogenesis, as shown by significantly lowered ATP production and ATP levels, decreased gene expression, and the onset of developmental defects. Examining neural tissues commonly affected by mitochondrial disease, we found that DNP exposure also inhibited motor neuron axon arbor outgrowth and the proper formation of the retina. We observed and quantified the molecular and physiological progression of mitochondrial dysfunction during development with this new model of OXPHOS dysfunction, which has great potential for use in diagnostics and therapies for mitochondrial disease.
Insights
Mitochondrial dysfunction in zebrafish, induced by 2,4-dinitrophenol (DNP), impairs development and neural tissue formation. This study models mitochondrial disease progression, offering potential for new diagnostics and therapies.
Area of Science:
- Developmental Biology
- Mitochondrial Biology
- Toxicology
Background:
- Mitochondrial diseases have poorly understood causes, limited treatments, and insensitive diagnostics.
- Disrupted oxidative phosphorylation (OXPHOS) is a common hallmark of mitochondrial disorders.
- 2,4-dinitrophenol (DNP) uncouples OXPHOS, serving as a research tool and environmental toxicant.
Purpose of the Study:
- To investigate the molecular and physiological progression of mitochondrial dysfunction during zebrafish development.
- To establish a zebrafish model for studying mitochondrial disorders and evaluating potential diagnostics and therapies.
Main Methods:
- Induction of OXPHOS inhibition in zebrafish embryos using 2,4-dinitrophenol (DNP).
- In vivo respirometry to assess ATP production and mitochondrial function.
- Gene expression analysis of mitochondrial and nuclear genes.
- Observation of developmental milestones and neural tissue formation (retina, motor neurons).
Main Results:
- DNP-treated zebrafish initially compensated for OXPHOS inhibition by increasing mitochondrial biogenesis and glycolysis, maintaining ATP levels.
- Beyond mid-embryogenesis, DNP-treated embryos showed impaired mitochondrial function, reduced ATP, developmental defects, and inhibited neural tissue development.
- The study successfully modeled the progression of mitochondrial dysfunction and its impact on neural development.
Conclusions:
- Early-stage mitochondrial dysfunction can be compensated for through adaptive responses, but these are insufficient to prevent later developmental defects.
- The DNP-induced zebrafish model effectively recapitulates key aspects of mitochondrial disease progression.
- This model holds significant promise for the development of novel diagnostic and therapeutic strategies for mitochondrial disorders.
